SCHEMBL8101124

SCHEMBL8101124

CCC(C)NC1CCc2[nH]c3ccc(NC(=O)c4ccccc4Cl)cc3c2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.47
JAK1 P23458 2/20 0.47
HTR1F P30939 1/20 0.45
HTR1A P08908 2/20 0.43
HTR1B P28222 2/20 0.43
HTR1D P28221 1/20 0.43
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
F2R P25116 1/20 0.42
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
HTR1E P28566 1/20 0.41
HTR7 P34969 1/20 0.41
OPRM1 P35372 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7663031 0.88 JAK2 (0.49) JAK2JAK1HTR1FHTR1AHTR1B
SCHEMBL8116663 0.86 JAK2 (0.46) JAK2JAK1HTR1FALDH1A1LMNA
SCHEMBL8116377 0.85 F2R (0.47) HTR1FHTR1AHTR1BHTR1DALDH1A1
SCHEMBL8101122 0.83 HTR1F (0.55) JAK2JAK1HTR1FALDH1A1LMNA
SCHEMBL7662558 0.82 HTR1F (0.67) HTR1FHTR1AHTR1BHTR1DALDH1A1
Hydrochloric Acid SCHEMBL7666106 0.81 HTR1F (0.66) HTR1FHTR1AHTR1BHTR1DALDH1A1
SCHEMBL7655587 0.81 JAK2 (0.51) JAK2JAK1HTR1FHTR1AHTR1B
SCHEMBL7663021 0.81 HTR1F (0.67) JAK2JAK1HTR1FALDH1A1CHRM5
SCHEMBL8100843 0.81 HTR1F (0.49) HTR1FHTR1AHTR1BHTR1DALDH1A1
SCHEMBL8116660 0.81 HTR1F (0.49) JAK2JAK1HTR1FHTR1AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS VALORISATION HSJ LP (CA) 2026-05-07 US disclosed
EP-0749962-B1 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles LILLY CO ELI (US) 2000-11-02 EP disclosed
US-5814653-A SUMATRIPTAN FOR RELIEF OF MIGRAINE PAIN AND OTHER DISORDERS ASSOCIATED WITH PEPTIDE EXTRAVASATION DIE TO STUMULATION OF THE TRIGEMINAL GANGLIA; 5-HT 1F AGONISTS ELI LILLY AND COMPANY (US) 1998-09-29 US disclosed
US-5708187-A MIGRANE HEADACHES ELI LILLY AND COMPANY (US) 1998-01-13 US disclosed
EP-0749962-A1 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles ELI LILLY AND COMPANY (US) 1996-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125645-A1 METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS HTR1F, HTR1A, HTR1D JAK2 120/4885JAK1 116/4885HTR1F 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.